Epizyme has been pursuing a novel target in multiple myeloma, and now it has reported positive data from mouse studies for a potential first-in-class therapy.
The drug, dubbed EPZ-719, targets the enzyme SETD2, which the company's scientists believe helps support a cancer-causing mutation that's found in about 15% of multiple myeloma cases. EPZ-719 significantly inhibited tumor growth in mice with or without the driver mutation, according to data presented at the European Hematology Association virtual congress.